HK13081A - 4-phenylpiperidine compounds - Google Patents

4-phenylpiperidine compounds

Info

Publication number
HK13081A
HK13081A HK130/81A HK13081A HK13081A HK 13081 A HK13081 A HK 13081A HK 130/81 A HK130/81 A HK 130/81A HK 13081 A HK13081 A HK 13081A HK 13081 A HK13081 A HK 13081A
Authority
HK
Hong Kong
Prior art keywords
phenylpiperidine compounds
phenylpiperidine
compounds
Prior art date
Application number
HK130/81A
Other languages
English (en)
Inventor
J A Christensen
R F Squires
Original Assignee
Ferrosan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK13081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrosan As filed Critical Ferrosan As
Publication of HK13081A publication Critical patent/HK13081A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK130/81A 1973-01-30 1981-04-02 4-phenylpiperidine compounds HK13081A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (1)

Publication Number Publication Date
HK13081A true HK13081A (en) 1981-04-10

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
HK130/81A HK13081A (en) 1973-01-30 1981-04-02 4-phenylpiperidine compounds

Country Status (20)

Country Link
US (2) US3912743A (fr)
JP (2) JPS5946216B2 (fr)
AT (1) AT333759B (fr)
BE (1) BE810310A (fr)
CA (1) CA1038390A (fr)
CH (1) CH592059A5 (fr)
DE (1) DE2404113C2 (fr)
DK (1) DK149843C (fr)
ES (2) ES422734A1 (fr)
FI (1) FI57932C (fr)
FR (1) FR2215233B1 (fr)
GB (1) GB1422263A (fr)
HK (1) HK13081A (fr)
IE (1) IE38801B1 (fr)
IT (1) IT1054157B (fr)
LU (2) LU69264A1 (fr)
NL (2) NL179187C (fr)
NO (1) NO144568C (fr)
PH (1) PH10383A (fr)
SE (1) SE401827B (fr)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
DK149624C (da) * 1983-03-07 1987-02-02 Ferrosan As Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (fr) * 1984-12-13 1987-05-27 Beecham Group Plc Dérivés de la pipéridine à activité gastro-intestinale
EP0223334B1 (fr) * 1985-08-10 1991-07-10 Beecham Group Plc Procédé de préparation d'aryl-pipéridine-carbinols
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
NO158038C (no) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As Kabel.
EP0223403B1 (fr) * 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (da) * 1989-11-22 1989-11-22 Ferrosan As Ny heterocyklisk kemi
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
DE4112353A1 (de) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (fr) * 1993-08-19 1995-02-22 Novo Nordisk A/S Dérivés de pipéridine, leur préparation et leur utilisation dans le traitement des maladies neurodégénératives
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
CN1068597C (zh) * 1995-05-17 2001-07-18 诺沃挪第克公司 制备4－芳基－哌啶衍生物的方法
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
TR199800409T1 (xx) * 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (fr) * 1996-05-30 1997-11-30 Shu-Zhong Wang Methode de preparation de chlorhydrate de paroxetine amorphe
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (fr) 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Procédé pour la préparation de hydrochlorure cristallin de paroxetine
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
US6180648B1 (en) * 1997-04-07 2001-01-30 Biostream Therapeutics, Inc. Analogs of cocaine
GB9710004D0 (en) 1997-05-17 1997-07-09 Knoll Ag Chemical process
EP0986389B1 (fr) * 1997-05-29 2004-10-13 Smithkline Beecham Corporation Nouveau procede
CN1092654C (zh) * 1997-06-10 2002-10-16 斯索恩有限公司 4－苯基哌啶类化合物
SK283394B6 (sk) 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
CA2212451C (fr) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Preparation stereoselective et utile de 4-arylpiperidines substituees en position 3
ES2137131B1 (es) * 1998-02-06 2000-09-16 Vita Invest Sa Derivado de piperidinona procedimiento de obtencion y procedimiento para su utilizacion.
HUP0101215A3 (en) * 1998-03-16 2002-05-28 Smithkline Beecham Plc Chrystalline form of paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
EA200001050A1 (ru) * 1998-04-09 2001-04-23 Смитклайн Бичам Плс Малеат пароксетина
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
EP0969002B1 (fr) 1998-06-29 2003-08-27 SUMIKA FINE CHEMICALS Co., Ltd. L-Tartrate de trans-(-)-4-(4-fluorophenyl)-3-hydroxymethylpiperidines et leur procédé de préparation
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
CA2339857A1 (fr) * 1998-08-07 2000-02-17 Neal Ward Procede de preparation d'une forme anhydre non cristalline d'hydrochlorure de paroxetine
CA2346537A1 (fr) 1998-10-07 2000-04-13 Gian Luca Araldi Heterocycles monomeres et dimeres et leurs utilisations therapeutiques
EP1408039A3 (fr) * 1998-11-30 2004-05-12 Smithkline Beecham Plc Solvates mixtes de propan-2-ol et de paroxetine
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
WO2000037443A1 (fr) * 1998-12-22 2000-06-29 Pentech Pharmaceuticals, Inc. Procede de preparation d'intermediaires et de derives de arylpiperidine carbinol
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
KR100759159B1 (ko) * 1999-07-01 2007-09-14 이탈파마코 에스.피.에이. 파록세틴과 사이클로덱스트린 또는 사이클로덱스트린유도체의 컴플렉스
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (it) * 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
AU1037701A (en) * 1999-10-20 2001-04-30 Smithkline Beecham Plc Process for the preparation of 4-(fluorophenyl)piperidine esters
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
CZ20023694A3 (cs) 2000-05-12 2003-05-14 Synthon B. V. Tosylátové soli 4-(p-fluorfenyl)-piperidin-3-methanolů
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
EP1301508A1 (fr) * 2000-07-17 2003-04-16 Smithkline Beecham Plc Nouveaux procedes de preparation de derives 4-phenylpiperidine
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
WO2002028834A1 (fr) * 2000-10-06 2002-04-11 Smithkline Beecham P.L.C. Procede de preparation de carbonols d'aryl-piperidine et produits intermediaires de ces derniers
WO2002032870A1 (fr) * 2000-10-20 2002-04-25 Smithkline Beecham P.L.C. Procede de preparation de composes de -4-aryle piperidine substitue en position 3
EP1347960B1 (fr) * 2001-01-04 2004-11-17 Ferrer Internacional, S.A. Procede de preparation de (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1362032A2 (fr) * 2001-02-24 2003-11-19 Spurcourt Limited Procede de preparation de la paroxetine et intermediaires a cet usage
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AU2002318185A1 (en) * 2001-06-13 2002-12-23 Teva Pharmaceutical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
CA2456233A1 (fr) * 2001-08-02 2003-03-13 Spurcourt Limited Sel d'isethionate de paroxetine, procede de preparation et utilisation dans le traitement de la depression
MXPA04003358A (es) * 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
NZ532432A (en) * 2001-10-22 2005-02-25 Synthon Bv N-formyl paroxetine compounds and their use in a synthetic route for obtaining paroxetine
WO2003057150A2 (fr) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. Formulation pharmaceutique d'hydrochlorure stable et procédé de préparation
US6956121B2 (en) * 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (ko) * 2002-07-05 2005-03-17 임광민 피페리딘 화합물의 새로운 제조방법
WO2004039778A1 (fr) * 2002-11-01 2004-05-13 Neurosearch A/S Nouveaux derives de piperidine et leur utilisation en tant qu'inhibiteurs de recaptage de neurotransmetteurs de la monoamine
WO2004043921A1 (fr) * 2002-11-11 2004-05-27 Natco Pharma Limited Nouveau procede de preparation de 4-aryl-3-hydroxymethyl-1-methylpiperidines
EA009646B1 (ru) 2003-05-30 2008-02-28 Рэнбакси Лабораториз Лтд. Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
ES2319539T3 (es) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006018318A1 (fr) * 2004-08-18 2006-02-23 Synthon B.V. Compositions liquides de paroxetine
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
WO2006102283A2 (fr) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Acides beta-lactamylalcanoiques destines au traitement des troubles premenstruels
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
EP1879875A1 (fr) * 2005-04-22 2008-01-23 Wyeth Formes cristallines de {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}chlorhydrate amine
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
EP2317316A3 (fr) 2005-07-08 2011-06-15 Braincells, Inc. Procédés permettant d'identifier l'agent et les conditions qui modulent la neurogénèse
EP1910346B1 (fr) 2005-07-19 2019-02-27 Azevan Pharmaceuticals, Inc. Antagonistes la vasopressine, du type beta-lactamyl phenylalanine, cysteine et serine
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1998773A2 (fr) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (fr) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation de la neurogenèse par des ligands mélatoninergiques
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
MX2010002692A (es) 2007-09-13 2010-06-01 Concert Pharmaceuticals Inc Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
EP2288345B1 (fr) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Produits psycho-pharmaceutiques
CA2727174A1 (fr) * 2008-06-20 2010-01-21 Jiangao Song Agonistes des recepteurs gpr119 aryles et utilisations associees
NZ592543A (en) 2008-11-14 2013-02-22 Theravance Inc 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
JP5847813B2 (ja) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
PL3351104T3 (pl) 2010-07-01 2021-06-14 Azevan Pharmaceuticals, Inc. Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
WO2013115163A1 (fr) 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de paroxétine
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US20250042855A1 (en) * 2021-12-02 2025-02-06 The Johns Hopkins University Peripherally and luminally-restricted inhibitors of the serotonin transporter as treatments for disorders of gastrointestinal motility and gut-brain axis
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
GB2636182A (en) 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Also Published As

Publication number Publication date
PH10383A (en) 1977-03-02
NO144568B (no) 1981-06-15
NL930003I2 (nl) 1994-03-01
JPS5946216B2 (ja) 1984-11-10
IT1054157B (it) 1981-11-10
FI57932B (fi) 1980-07-31
AT333759B (de) 1976-12-10
SE401827B (sv) 1978-05-29
US4007196A (en) 1977-02-08
DK149843C (da) 1987-06-15
GB1422263A (en) 1976-01-21
DK149843B (da) 1986-10-13
JPS49101385A (fr) 1974-09-25
IE38801B1 (en) 1978-06-07
JPS5948826B2 (ja) 1984-11-29
CA1038390A (fr) 1978-09-12
ATA69674A (de) 1976-04-15
NO144568C (no) 1981-09-23
FI57932C (fi) 1980-11-10
ES556013A0 (es) 1987-07-16
LU88398I2 (fr) 1994-05-04
NL7401189A (fr) 1974-08-01
US3912743A (en) 1975-10-14
DE2404113C2 (de) 1985-07-11
FR2215233A1 (fr) 1974-08-23
NL179187B (nl) 1986-03-03
NL179187C (nl) 1986-08-01
NO740272L (no) 1974-07-31
BE810310A (fr) 1974-05-16
ES422734A1 (es) 1976-04-01
IE38801L (en) 1974-07-30
ES8707224A3 (es) 1987-07-16
LU69264A1 (fr) 1974-04-10
DE2404113A1 (de) 1974-08-08
JPS58174363A (ja) 1983-10-13
FR2215233B1 (fr) 1977-01-28
CH592059A5 (fr) 1977-10-14

Similar Documents

Publication Publication Date Title
PH10383A (en) 4-phenylpiperidine compounds
JPS514464A (en) Junkatsuyu no saiseihoho
JPS5133102A (en) Sekitan no gasukahoho
JPS511558A (en) Atsushukuhizumi no hikui shirokisanerasutomaa
ZM16774A1 (en) Compounds
JPS5195985A (en) Fukugodenkyokutai no seizoho
AU7031674A (en) Novel compounds
AU6977274A (en) Compounds
ZA74944B (en) Substituted pyrrolidinemethanols
ZA744918B (en) Substituted bebzofurans
KE2889A (en) Pathalocyanine compounds
JPS5152867A (en) yobihyojibanoyobi hizukehyojiban no kudosochi
JPS5110895A (en) Horikaaboneeto no seizohoho
AU7040074A (en) Compounds
IL45321A0 (en) Substituted phenylglycylcephalosporins
JPS5137457A (en) Sokohoisuto no itsusoboshisochi
ZA744584B (en) Novel n-hydroxy-amidine compounds
JPS517064A (en) Goseimeiboku no seizohoho
ZA747405B (en) Substituted acetamidocephalosporins
JPS511508A (en) Kazangarasunyoru tainetsushogekiseitojiki no seizoho
JPS5129210A (en) Mushukaninnikumatsu no seizoho
AU6436474A (en) Compounds
AU6677774A (en) Triphenyl-tin compounds
AU7528074A (en) Compounds
GB1408729A (en) Sulphilimine compounds